Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
August 2018
-
Press Release
Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission
Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein… -
Press Release
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1… -
Key Release
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase… -
Key Release
Novartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer
Basel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von… -
Key Release
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
July 2018
-
Press Release
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and… -
Press Release
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is… -
Press Release
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with… -
Press Release
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million… -
Press Release
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to… -
Press Release
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer… -
Key Release
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…